Description:

The use of the recent FDA approved, and pipeline antifungal drugs are often not addressed in guidelines for invasive fungal infections (due to recent approval, or lack thereof) but still demonstrate utility to the clinical practitioner. Knowledge of new and pipeline antifungals is critical given growing drug resistance to fungi, and the emergence of fungi with limited treatment options like Candida auris. This presentation serves to inform 

clinical inpatient pharmacists on emerging antifungals, highlighting how recently approved and pipeline agents are increasingly essential for managing rising fungal resistance, high‑mortality invasive infections, and the significant limitations of existing therapies, especially as critical pathogens continue to threaten vulnerable, immunocompromised patients.

Target Audience: 

Pharmacists (PharmD)

Learning Objectives:

At the completion of this activity, learners will be able to:Recall DKA treatment goals.

1. Identify limitations with the current landscape of traditional antifungal agents 
2. Assess the clinical utility of novel antifungal agents 
3. Discuss pertinent clinical trials of novel antifungal agents

Assembly Bills 1195 & 241- Culturally Appropriate Care which is Free of Implicit Biases:

Learners are strongly encouraged to engage in self-directed learning related to the impact of implicit biases in this clinical area via the references provided below:

Suarez, D., Schneider, R., Girardi, M., LaRossa, G., Yeary, J., Kaser, T., Ancona, R., Bravo, P., Griffey, R. (2025). Social Determinants of Health and Health Literacy in Emergency Patients with Diabetic Ketoacidosis. Western Journal of Emergency Medicine, Volume 26 (No. 3), 381-386. LINK

Disclosure of Financial or In-Kind Commercial Support & Conflict of Interest

No one involved in the planning or presentation of this educational activity have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. No financial or in-kind commercial support was received to produce or promote this educational activity.   

– Provider Designee/Verification:  Fozia Ferozalai, Ed.D. 

Committee Member(s)
Jennifer Biltoft, PharmD, MHA, BCPS has no relevant financial relationships to disclose at this time.
Yu Christine Chan, B.S. Pharm, BCCCP, BCPS has no relevant financial relationships to disclose at this time.
Hyunah Eom, PharmD has no relevant financial relationships to disclose at this time.
Phipson Wu, PharmD, BCPS has no relevant financial relationships to disclose at this time.
Laura Zhang, Pharm. D. has no relevant financial relationships to disclose at this time.

Moderator(s) 
Phipson Wu, PharmD, BCPS has no relevant financial relationships to disclose at this time.

Peer Reviewer(s) 
Monica Awad, Monica Awad, PharmD, BCPPShas no relevant financial relationships to disclose at this time.

Planner(s)
Monica Awad, Monica Awad, PharmD, BCPPShas no relevant financial relationships to disclose at this time.
Jennifer Biltoft, PharmD, MHA, BCPS has no relevant financial relationships to disclose at this time.
Yu Christine Chan, B.S. Pharm, BCCCP, BCPS has no relevant financial relationships to disclose at this time.
Hyunah Eom, PharmD has no relevant financial relationships to disclose at this time. 
Phipson Wu, PharmD, BCPS has no relevant financial relationships to disclose at this time.
Laura Zhang, Pharm. D. has no relevant financial relationships to disclose at this time.